iGMDRD191

Canonical SMILES: CC1=CC=C(C=C1)C2=C(N(C3=C2C(=NC=N3)N)CCCO)C(=O)CF

InChI: InChI=1S/C18H19FN4O2/c1-11-3-5-12(6-4-11)14-15-17(20)21-10-22-18(15)23(7-2-8-24)16(14)13(25)9-19/h3-6,10,24H,2,7-9H2,1H3,(H2,20,21,22)

InChI Key: IKLGYJACVCXYIL-UHFFFAOYSA-N

Loading, please wait...
Standard Name
Pubchem CID
Drug Status
Drug Type
Standard NameFMK
Pubchem CID644243
Drug StatusAlone
Drug TypeSmall Molecule

Drug Targets:

RSK

Drug Pathways:

Other, kinases

Drug-model tissue-cancer distribution: Bubble Plot

undefinetissue: undefine cancer: undefined model num: 0undefinedtissue: undefined cancer: PANCAN model num: 2LYMPtissue: LYMP cancer: LYMPH model num: 0LYMPHtissue: LYMPH cancer: Diffuse Large B-Cell Lymphoma (DLBCL) model num: 1BONtissue: BON cancer: BONE model num: 0BONEtissue: BONE cancer: Acute Myeloid Leukemia (AML) model num: 1PANCREAtissue: PANCREA cancer: PANCREAS model num: 0PANCREAStissue: PANCREAS cancer: Pancreatic Adenocarcinoma (PAAD) model num: 1SKItissue: SKI cancer: SKIN model num: 0SKINtissue: SKIN cancer: Cutaneous Melanoma (SKCM) model num: 1

Drug-gene pathway enrichments

8reactome: Signal Transduction4reactome: Disease4reactome: RNA Polymerase II Transcription4reactome: Gene expression (Transcription)4reactome: Diseases of signal transduction4reactome: Generic Transcription Pathway3kegg: FoxO signaling pathway - Homo sapiens (human)3wikipathways: Signaling Pathways in Glioblastoma3reactome: Developmental Biology3reactome: Signaling by WNT

Drug-gene GO enrichments

7MF: protein binding5CC: nucleoplasm5CC: nucleus5CC: cytosol4CC: cytoplasm4MF: beta-catenin binding4CC: plasma membrane3MF: DNA binding3MF: protein serine/threonine kinase activity3MF: transcription coactivator activity

Drug-Gene: Aster Plot


Loading, please wait...
Gene ID
Gene Name
Model Num.
8289 ARID1A 1
2033 EP300 2
256646 NUTM1 1
139285 AMER1 1
Showing 1 to 4 of 7 rows

Gene in drug-gene network: Network Plot

selumetinib in BRAF mutant tumorsselumetinib in BRAF mutant tumorskinetin ribosidekinetin ribosideCDK4/6 inhibitorsCDK4/6 inhibitorsBMS-754807BMS-754807MEK inhibitorsMEK inhibitorscetuximabcetuximabcytochalasin.Bcytochalasin.BVER 155008VER 155008BI-2536BI-2536ubistatin Bubistatin BABT737ABT737PanitumumabPanitumumabFedratinibFedratinibPLX-4720PLX-4720DabrafenibDabrafenibVemurafenibVemurafenibChloropentafluorobenzeneChloropentafluorobenzeneBinimetinib (MEK162)Binimetinib (MEK162)RefametinibRefametinibTrametinibTrametinibNRASNRASLY3023414LY3023414GSK2636771GSK2636771BMS-536924BMS-536924BRD63610BRD63610BIX01294BIX01294EverolimusEverolimusCompound.1541ACompound.1541Abistramide Abistramide APARP inhibitorsPARP inhibitorsmTOR inhibitorsmTOR inhibitorsOlaparibOlaparibPI3K pathway inhibitorsPI3K pathway inhibitorsMK-2206MK-2206zebularinezebularineAZD8186AZD8186GSK690693GSK690693trastuzumab alonetrastuzumab aloneSirolimusSirolimusPTENPTENSN-38SN-38tipifarnib-P2tipifarnib-P2CHEMBL399379CHEMBL399379CHIR-99021CHIR-99021isoevodiamineisoevodiaminenakiterpiosinnakiterpiosinSepantroniumSepantroniumTAOK1TAOK1FK 866FK 866manumycin.Amanumycin.AParthenolideParthenolideML 210ML 210triacsin Ctriacsin CGMX1778GMX1778nutlin 3nutlin 3NUTM1NUTM1neopeltolideneopeltolideIdarubicinIdarubicinSB225002SB225002leucascandrolide Aleucascandrolide ALY 2183240LY 2183240NPC26NPC26(-)-gallocatechin-3-O-gallate(-)-gallocatechin-3-O-gallateTW-37TW-37Nsc 632839Nsc 632839BRD7137BRD7137CD437CD437EP300EP300Compound 44Compound 44rotenonerotenoneQuiflaponQuiflaponISX-9ISX-9DC-45-A2DC-45-A2BRD4132BRD4132avrainvillamideavrainvillamideVX-680VX-680oligomycin.Aoligomycin.AgossypolgossypolPAC-1PAC-1AMER1AMER1NSC95397NSC95397itraconazoleitraconazoleBRD6368BRD6368Tyrphostin AG 1478Tyrphostin AG 1478pevonedistatpevonedistatteniposideteniposideGemcitabineGemcitabineARID1AARID1AFMKFMK

Models in FMK

Model
Level
Reference ID
Tissue
Cancer
Drug
Clinical Response
Source
MUT(C15orf55) gene GDSC undefined PANCAN FMK sensitivity in vitro
MUT(NRAS)|PWU(JAK-STAT) mix GDSC undefined PANCAN FMK sensitivity in vitro
MUT(ARID1A)|MUT(EP300)|PWU(JAK-STAT)|PWU(Wnt) mix GDSC LYMPH Diffuse Large B-Cell Lymphoma (DLBCL) FMK sensitivity in vitro
¬MUT(NRAS)&PWU(JAK-STAT) mix GDSC BONE Acute Myeloid Leukemia (AML) FMK sensitivity in vitro
PWU(MAPK_PI3K) mix GDSC PANCREAS Pancreatic Adenocarcinoma (PAAD) FMK sensitivity in vitro
MUT(EP300)|MUT(FAM123B)|MUT(PTEN)|MUT(TAOK1) mix GDSC SKIN Cutaneous Melanoma (SKCM) FMK sensitivity in vitro
Showing 1 to 6 of 6 rows

​​​​

SITE
DATATYPES
CLASSFICATION
Map

Copyright © 2018 Modellab | All Rights Reserved

Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.